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Abstract
There is increasing concern regarding the association between certain methicillin-resistant Staphylococcus aureus (MRSA) genotypes and
poor clinical outcome. To assess this issue, a large cohort of 579 subjects with MRSA bacteraemia was prospectively followed from June
2008 to December 2009, in 21 hospitals in Spain. Epidemiology, clinical data, therapy, and outcome were recorded. All MRSA strains were
analysed in a central laboratory. Presence of a haematogenous seeding infection was the dependent variable in an adjusted logistic regression
model. Of the 579 patients included in the study, 84 (15%) had haematogenous seeding infections. Microdilution vancomycin median MIC
(IQR) was 0.73 (0.38–3) mg/L. Most MRSA isolates (n = 371; 67%) belonged to Clonal Complex 5 (CC5) and carried an SCCmec element
type IV and agr type 2. Isolates belonging to ST8-agr1-SCCmecIV, ST22-agr1-SCCmecIV and ST228-agr2-SCCmecI—a single locus variant of
ST5—accounted for 8%, 9% and 9% of the isolates, respectively. After adjusting by clinical variables, any of the clones was associated with
increased risk of haematogenous seeding infections. Higher vancomycin MIC was not identiﬁed as an independent risk factor, either. In
contrast, persistent bacteraemia (OR 4.2; 2.3–7.8) and non-nosocomial acquisition (3.0; 1.7–5.6) were associated with increased risk.
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Background
Staphylococcus aureus is one of the microorganisms most
frequently involved in bacteraemia worldwide. Compared with
other microorganisms, it is associated with higher rates of
morbidity and mortality [1].
Haematogenous seeding infections are a frequent feature of
S. aureus bacteraemia [2]. This clinical scenario is observed in
approximately 30–40% of episodes and can be predicted by the
presence of factors such as community acquisition, unknown
source, suggestive skin lesions, persistent fever and positive
follow-up blood cultures [3].
Infective endocarditis (IE) caused by S. aureus is probably
the most relevant complication due to this microorganism [4].
Notably, with mortality rates between 40% and 50%, meth-
icillin-resistant S. aureus (MRSA) IE is associated with worse
prognosis than methicillin-sensitive S. aureus IE [5].
Higher vancomycin minimum inhibitory concentration
(V-MIC), has been described as an independent predictor of
treatment failure [6] and complicated bacteraemia [7]. Given
that most clinical studies do not include molecular microbi-
ology assessment, it is not known whether certain MRSA
genotypes are associated with worse outcome and enhanced
risk of complications. However, a few studies have taken into
account strain clonality in their analyses of outcome predictors
with contradictory results [8–11]. In this study we evaluated
the inﬂuence of MRSA genotypes on the appearance of
haematogenous seeding infections in a large cohort of
bacteraemia episodes.
Methods
Study period and patients
The study was conducted from June 2008 to December 2009
in 21 hospitals in Spain. Four hospitals had <500 beds; nine had
500–1000 beds; and eight had >1000 beds. An infectious
disease specialist prospectively followed up adult patients
(>16 years old) with MRSA blood cultures previously detected
at the microbiology laboratory, and excluded those that did
not meet the inclusion criteria (lack of signs and symptoms
consistent with sepsis). A standardized protocol with demo-
graphic and clinical information was applied. Strains were sent
to a central laboratory for further studies. The ﬁrst isolate of
each episode was used for the analysis.
Study design
With the data collected, MRSA bacteraemia episodes with and
without observed haematogenous seeding infections were
compared. To analyse whether there is an association with
genetic background, we carried out an adjusted multivariate
analysis in which presence of haematogenous seeding infection
was the dependent variable and MRSA clonal complex was the
independent variable of interest.
Deﬁnitions
The MRSA bacteraemia was deﬁned as the presence of at least
one positive blood culture for MRSA in a sample from a patient
with clinical ﬁndings consistent with infection. When a focal
infection different from bacteraemia portal of entry was
diagnosed, the episode was considered a haematogenous
seeding infection. Clinical data were interpreted accordingly
with the infectious diseases specialist criteria.
Clinical variables. Co-morbidity was measured using the Charl-
son score, which stratiﬁes the associated diseases on an ordinal
scale. Three acquisition categories were considered: (i) noso-
comial bacteraemia was considered when the episode was
diagnosed at least 48 h after hospital admission, either to the
ICU or to a conventional ward (non-ICU), and when there were
no signs or symptoms of infection at admission; (ii) health-
care-related bacteraemia was diagnosed following Friedman’s
criteria; and (iii) community acquisition was considered when
MRSA bacteraemia was diagnosed within 48 h of admission and
when no previous contact with the healthcare system was
recorded. The bacteraemia portal of entrywas deﬁned following
CDC criteria [12]. Endocarditis was diagnosed in cases that met
modiﬁed Duke criteria [13]. The severity of sepsis was
determined on the basis of the Pitt score. Initial antibiotic was
deﬁned as the antibiotics administered in the ﬁrst 48 h after
bacteraemia onset. Deﬁnitive treatment was considered the
antimicrobials administered after performing microbiological
sensitivity tests. Antibiotic treatment was considered appropri-
ate when the MRSA isolate was susceptible to at least one of the
antibiotics administered, following the current CLSI break-
points, with the exception of aminoglycosides, which were
considered inappropriate, regardless of the sensitivity tests.
Early intervention was considered when the catheter or foreign
body was removed, or when a surgical procedure or drainage of
infected source was performed within the ﬁrst 48 h. Persistent
bacteraemia was diagnosed when MRSA was isolated in blood
cultures more than 48 h after the ﬁrst dose of appropriate
antibiotic. Relapse was diagnosed within 4 weeks after the end
of therapy.
Susceptibility testing and molecular epidemiology of MRSA
isolates
Each hospital identiﬁed the isolates and performed preliminary
susceptibility tests. Further antimicrobial susceptibility testing
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of all MRSA isolates was carried out in a central laboratory
using the microdilution method. Commercial panels were used
(ESTEN 2009, Sensititre; Izasa, Barcelona, Spain), and results
were interpreted following the guidelines of the National
Committee for Clinical Laboratory Standards (currently the
CLSI).
Pulsed-ﬁeld gel electrophoresis (PFGE) was performed after
SmaI restriction of chromosomal DNA in all isolates, following
a previously published method [14]. Restriction patterns were
interpreted following the criteria published elsewhere [15]. To
determine the multilocus sequence type (MLST) [16] and the
staphylococcal chromosome cassette mec (SCCmec) types
[17], we studied representative isolates of each PFGE type and
subtype. Accordingly, MLSTs and SCCmec types were further
inferred for all the strains. MLST sequences types (ST) were
assigned through the MLST database (http://www.mlst.net),
and clonal complexes (CC) were deﬁned using the EBURST v3
algorithm (http://eburst.mlst.net). The agr polymorphism and
the presence of genes in all the isolates were examined by
PCR, following previously described methodology [18].
Statistical analysis
Qualitative and stratiﬁed continuous variables were compared
using Fisher’s exact test or Pearson’s chi-squared test. Relative
risks were calculated with 95% CI in a univariate analysis.
Multivariate analysis was performed by using a logistic regres-
sion model in which presence of haematogenous seeding
infection was the dependent variable. All the variables with
theoretical clinical signiﬁcance and those that achieved a p value
<0.10 in the univariate analysis were included in the multivar-
iate analysis, and adjusted OR were calculated with 95% CI. All
analyses were performed using SPSS.v21 (Microsoft, Chicago,
IL, USA).
Ethical considerations
The study was approved by the Spanish Network for Research
in Infectious Diseases (REIPI) as well as the Institutional Review
Board of each participating centre. Because no direct patient
contact was planned, the requirement for informed consent
was waived. The data were de-identiﬁed in each centre and
only then transferred for analysis.
Results
Overall, 579 episodes of MRSA bacteraemia were included in
the analysis. Their main characteristics are summarized in
Table 1. Of these, 84 (15%) were diagnosed with haematog-
enous seeding infections. Twenty-ﬁve PFGE types were found
among the 579 isolates (Fig. 1) [19]. A dominant PFGE
genotype (pulse-type 2) was found in 371 isolates (67%), all of
which belonged to CC5 (ST125 and ST146). They carried an
SCCmec element type IV and agr type 2. Forty-seven (9%)
isolates of clonal type ST228-agr2, a single locus variant of
ST5, were considered a separate clone based on the SCCmec
polymorphism type I. CC22-SCCmecIV-agr1 and CC8-
SCCmecIV-agr1 accounted for 9% and 8%, respectively, of
all the strains studied. CC5, CC228 and non-CC5/CC8/
CC22/ST228 microdilution V-MIC50 and V-MIC90 were 0.75
and 1.0 mg/L, whereas those of CC22 and CC8 were
0.75 mg/L.
TABLE 1. Summary of episodes of methicillin-resistant
Staphylococcus aureus bacteraemia
Clinical characteristics (n = 579) n (%)
Age
Mean (SD) 69.1 (14.3)
Gender
Female 194 (34)
Charlson
Median (ICR) 3 (2–6)
McCabe
Non-fatal 279 (49)
Ultimately fatal 212 (37)
Rapidly fatal 82 (14)
Portal of entry
Vascular catheter 218 (38)
Unknown 123 (21)
Skin and soft tissues 81 (14)
Lower respiratory tract 70 (12)
Surgical site infections 36 (6)
Urinary tract 28 (5)
Haematogenous seeding infection 84 (15)
Endocarditis 32
Bone and joint infection 28
Lung 6
Endophthalmitis 5
Spleen 5
Central nervous system 4
Liver 1
Other 9
Persistent bacteraemia 93 (23)
Foreign body presence 270 (47)
Acquisition
Nosocomial 338 (59)
Healthcare-related 238 (38)
Community 20 (4)
Pitt score
Median (ICR) 1 (0–3)
Microbiological studies (n = 552)
agr type
II 419 (76)
I 122 (22)
III 11 (2)
MLST-SCCmec
CC5a—IV 371 (67)
CC22—IV 48 (9)
ST228—I 47 (9)
CC8—IV 44 (8)
Other 42 (8)
Microdilution vancomycin median MIC (IQR) (mg/L) 0.73 (0.38–3)
Initial treatment
Appropriate initial antibiotic 371 (66)
Source drainage or catheter withdrawal 205 (35)
MLST, multilocus sequence typing; ST, sequence type; CC, clonal complex;
SCCmec, staphylococcal cassette chromosome; IQR, interquartile range.
aCC5 includes ST125 and ST146.
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Impact of clonality on the appearance of haematogenous
seeding infections
Haematogenous seeding infections were observed in 17% of the
episodes caused by strains belonging to CC22, and in 13–15% of
the episodes caused by strains belonging to the other genotypes
(ST228, CC8, CC5 and other clones grouped).
The following clinical factors were used to adjust the logistic
regression model: age ≤70 years, portal of entry, foreign body
presence, acquisition, persistent bacteraemia, early intervention
on portal of entry and appropriate initial antibiotic therapy.
Episodes with and without haematogenous seeding infections
had similar proportions of isolates with V-MIC > 1.5 mg/L in the
univariate analysis (p 0.74) (Table 2). After adjusting by the
former variables, any of the clones was associated with the
presence of haematogenous seeding infections. In contrast, only
persistent bacteraemia (OR 4.2; 2.3–7.8) and non-nosocomial
acquired episodes (3.0; 1.7–5.6) were associated with an
increased risk of haematogenous seeding infections (Table 3).
Notably, there were no differences between the most prevalent
clones, regarding the proportion of persistent bacteraemia
episodes (31% of ST228; 28% of ST146; 23% of ST 125; 28% of
ST22; 18% of ST8), nor between typical community clones
grouped (ST8/USA300 and ST398; n = 15) and the rest of the
clones (p 0.4). Lastly, persistence was also similar among the
nosocomial and non-nosocomial acquisition cohorts (24% and
21%, respectively) (p 0.4).
Discussion
Although deﬁnitions between studies differ widely, predictive
factors for complications among S. aureus bacteraemia have
(a) (b) (c)
FIG. 1. Molecular characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates. Shown from left to right are (a) a dendrogram
comparing pulsed-ﬁeld gel electrophoresis (PFGE) of SmaI macrorestriction fragments, (b) PFGE patterns and types (expressed by numbers),
followed by (c) multilocus sequence typing (MLST) and clonal complex (CC). The cut-off value to deﬁne PFGE types was set at 80%. Optimization and
band position tolerance were both set at 0.6%.
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been described. As in our study, persistent bacteraemia and
community acquisition are some of the most relevant identi-
ﬁed risk factors [2,3,20–24]. Surprisingly, the impact of
distinctive clones on the appearance of complications has
usually received little attention until now.
Taking advantage of a large well-characterized MRSA clinical
series from bacteraemia episodes, the present study sought to
determine whether there was an independent association
between certain genotypes and the appearance of haematog-
enous seeding infections. Although this question has been
addressed previously, inconsistent ﬁndings have been
reported.
Although some studies did not ﬁnd that MRSA genotypes
differ in their ability to cause invasive infections, others did
[25], thereby indicating a possible association between certain
MRSA clones and some virulence factors. Furthermore, the
inﬂuence of some S. aureus clonal groups on clinical outcome
has also been assessed. Fowler et al. [9] recently found an
association between CC5 and CC30, and haematogenous
complications. In a subsequent study, they identiﬁed 14
non-SCCmec-speciﬁc genes that were associated with com-
plicated bacteraemia [26]. Also, Wertheim et al. [27] observed
higher mortality in episodes of bacteraemia caused by certain
S. aureus CCs, and Seidl et al. [28] reported lower frequencies
of persistent MRSA bacteraemia in episodes caused by CC1. It
should be noted that all the former studies emphasized that all
the genotypes examined could cause invasive disease.
The scientiﬁc community is increasingly concerned about
the impact of higher V-MIC on outcome. In our study, loss of
vancomycin susceptibility was not identiﬁed as a risk factor for
haematogenous seeding infection. In this regard, two recent
clinical studies have demonstrated an association between
higher V-MIC and mortality [29], or complications [7] in
episodes of S. aureus bacteraemia that were not treated with
vancomycin. Those results revealed V-MIC to be a marker of
certain speciﬁc strain factors, which might be related to a
poorer outcome. To ascertain the effect of clonality on these
associations, molecular characterization of strains would have
been needed. However, it was not performed in those studies.
In this regard, Miller et al. [11] reported a strong association
between CC22 isolates with high V-MIC and endocarditis or
septic metastasis, among catheter-related MRSA bacteraemias.
In contrast with the former studies, in our cohort of
patients with MRSA bacteraemia, risk of haematogenous
seeding infections was not associated with any of the analysed
genotypes. A recent study of 159 patients with MRSA
bacteraemia did not ﬁnd an association between the risk of
persistent bacteraemia and their clonal complexes (CC5, CC8
and CC15), either [8]. Therefore, the ﬁndings from these two
studies would suggest that risk for complicated bacteraemia
would be inﬂuenced by factors that depend on the host and
the host’s interaction with the microorganism rather than by
the microorganism-speciﬁc characteristics.
All of these distinct results between studies might have
different plausible explanations. First, the different deﬁnitions
TABLE 2. Predictive factors for methicillin-resistant Staphy-
lococcus aureus haematogenous seeding infections: univariate
logistic regression analysis
Haematogenous
seeding,
n = 84
(15)
n (%)
Non-
haematogenous
seeding,
n = 492
(85)
n (%)
Univariate
p value
Age
<70 years 38 (45) 275 (56) 0.08
Gender
Female 30 (36) 162 (33) 0.62
Charlson
>5 points 19 (23) 144 (29) 0.20
McCabe
Non-fatal 42 (51) 235 (48)
Ultimately fatal 33 (40) 178 (37) 0.88
Rapidly fatal 8 (9) 74 (15) 0.22
Pitt score
>3 points 15 (18) 102 (21) 0.52
Portal of entry
Intravascular
catheter
24 (29) 193 (39)
Unknown 27 (32) 95 (19) 0.01
Surgical site 10 (12) 26(5) 0.01
Skin and soft tissues 18 (21) 62 (13) 0.01
Lower espiratory
tract
1 (1) 69 (14) 0.04
Foreign body presence 44 (52) 223 (45) 0.23
Acquisition
Non-nosocomiala 46 (56) 190 (39) 0.03
Persistent bacteraemia 30 (42) 63 (19) 0.001
Clonal complex
CC22 8 (9) 39 (9)
CC5 54 (67) 316 (68) 0.83
CC8 6 (8) 37 (8) 0.79
ST228 6 (8) 41 (9) 0.56
Other 7 (8) 30 (6) 0.82
Microdilution
vancomycin
MIC ≥ 1.5 mg/L
3 (4) 15 (3) 0.74
Early interventionb 37 (44) 167 (34) 0.07
Appropriate initial
antibiotic therapy
62 (74) 307 (63) 0.04
aHealthcare-acquired and community-acquired episodes are analysed together.
bEarly intervention included catheter withdrawal, drainage of source or surgery
within the ﬁrst 48 h after MRSA bacteraemia onset.
TABLE 3. Adjusted logistic regression analysis for presence
of haematogenous seeding infections among methicillin-resis-
tant Staphylococcus aureus bacteraemiaa
Adjusted OR (95% CI)
Clonal complex
CC22
CC5b 2.3 (0.7–7.5)
CC8 2.1 (0.5–9.6)
ST228 1.2 (0.2–5.7)
Other clones 3.4 (0.7–15.6)
Persistent bacteraemia 4.2 (2.3–7.8)
Non-nosocomial acquisition 3.0 (1.7–5.6)
aAdjusted by age, portal of entry, foreign body presence, acquisition, persistent
bacteraemia, early intervention on portal of entry and appropriate initial antibiotic
therapy.
bCC5 includes ST125 and ST146.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 361–367
CMI Gasch et al. MRSA genotypes and haematogenous seeding infections 365
used to assess outcomes. Second, the speciﬁc distribution of
clones and virulence genes in each region may inﬂuence the
existence of differences regarding their ability to cause compli-
cations [10]. For instance, our study registered a low presence
of typical community clones (i.e. ST8 harbouring PVL, ST398),
whereas the prevalence of these clones in other regions is
higher [30]. In contrast, most of the isolates in our study
belonged to CC5. Therefore, we cannot rule out the possibility
that some of the less prevalent clones in our cohort may be
associated with haematogenous seeding infections. Third, we
must also consider the possibility of a publication bias related to
the inclination to report positive results. Last, instead of
genotypes, certain virulence factors more frequently harboured
by some clones might be the authentic prognostic factors that
inﬂuence the ﬁnal outcomes. As a result, more clinical studies
will be required to analyse differences between clones regarding
their ability to increase the risk for worse outcomes, and
speciﬁcally, to cause haematogenous seeding infections.
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